Spruce Street Capital LP Makes New $6.87 Million Investment in Enliven Therapeutics, Inc. $ELVN

Spruce Street Capital LP purchased a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 446,084 shares of the company’s stock, valued at approximately $6,870,000. Enliven Therapeutics comprises approximately 2.3% of Spruce Street Capital LP’s investment portfolio, making the stock its 15th biggest holding.

Several other large investors also recently modified their holdings of the business. HighVista Strategies LLC boosted its position in shares of Enliven Therapeutics by 83.1% during the third quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock worth $5,304,000 after buying an additional 117,619 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of Enliven Therapeutics during the third quarter worth about $334,000. Patient Square Capital LP boosted its position in shares of Enliven Therapeutics by 2.0% during the third quarter. Patient Square Capital LP now owns 250,838 shares of the company’s stock worth $5,135,000 after buying an additional 5,000 shares during the period. Intech Investment Management LLC boosted its position in shares of Enliven Therapeutics by 15.6% during the fourth quarter. Intech Investment Management LLC now owns 16,729 shares of the company’s stock worth $258,000 after buying an additional 2,256 shares during the period. Finally, Fox Run Management L.L.C. acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth about $191,000. 95.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the transaction, the director directly owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.00% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $42.36 on Tuesday. The stock has a 50 day moving average price of $41.54 and a 200 day moving average price of $30.93. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $48.53. The stock has a market capitalization of $2.58 billion, a PE ratio of -25.37 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. As a group, research analysts forecast that Enliven Therapeutics, Inc. will post -1.71 EPS for the current year.

Wall Street Analysts Forecast Growth

ELVN has been the subject of several recent research reports. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Guggenheim initiated coverage on Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price objective for the company. Stifel Nicolaus initiated coverage on Enliven Therapeutics in a research report on Tuesday, June 9th. They set a “buy” rating and a $60.00 price objective for the company. HC Wainwright upped their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, The Goldman Sachs Group upped their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Enliven Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $63.40.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.